Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Median time to recovery 26% Improvement Relative Risk HCQ for COVID-19  Kirenga et al.  EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Prospective study of 56 patients in Uganda Faster recovery with HCQ (not stat. sig., p=0.2) Kirenga et al., BMJ Open Respiratory R.., Sep 2020 Favors HCQ Favors control

Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda

Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646
Sep 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Prospective 56 patients in Uganda, 29 HCQ and 27 control, showing 25.6% faster recovery with HCQ, 6.4 vs. 8.6 days (p = 0.20). There was no ICU admission, mechanical ventilation, or death.
Treatment delay is not specified but at least a portion of patients appear to have been treated early.
median time to recovery, 25.6% lower, relative time 0.74, p = 0.20, treatment 29, control 27.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kirenga et al., 9 Sep 2020, prospective, Uganda, peer-reviewed, 29 authors, dosage not specified.
This PaperHCQAll
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda
Dr Bruce Kirenga, Winters Muttamba, Alex Kayongo, Christopher Nsereko, Trishul Siddharthan, John Lusiba, Levicatus Mugenyi, Rosemary K Byanyima, William Worodria, Fred Nakwagala, Rebecca Nantanda, Ivan Kimuli, Winceslaus Katagira, Bernard Sentalo Bagaya, Emmanuel Nasinghe, Hellen Aanyu-Tukamuhebwa, Beatrice Amuge, Rogers Sekibira, Esther Buregyeya, Noah Kiwanuka, Moses Muwanga, Samuel Kalungi, Moses Lutaakome Joloba, David Patrick Kateete, Baterana Byarugaba, Moses R Kamya, Henry Mwebesa, William Bazeyo
BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646
Rationale Detailed data on the characteristics and outcomes of patients with COVID-19 in sub-Saharan Africa are limited. Objective We determined the clinical characteristics and treatment outcomes of patients diagnosed with COVID-19 in Uganda. Measurements As of the 16 May 2020, a total of 203 cases had been confirmed. We report on the first 56 patients; 29 received hydroxychloroquine (HCQ) and 27 did not. Endpoints included admission to intensive care, mechanical ventilation or death during hospitalisation. Main results The median age was 34.2 years; 67.9% were male; and 14.6% were <18 years. Up 57.1% of the patients were asymptomatic. The most common symptoms were fever (21.4%), cough (19.6%), rhinorrhea (16.1%), headache (12.5%), muscle ache (7.1%) and fatigue (7.1%). Rates of comorbidities were 10.7% (pre-existing hypertension), 10.7% (diabetes) and 7.1% (HIV), Body Mass Index (BMI) of ≥30 36.6%. 37.0% had a blood pressure (BP) of >130/90 mm Hg, and 27.8% had BP of >140/90 mm Hg. Laboratory derangements were leucopenia (10.6%), lymphopenia (11.1%) and thrombocytopenia (26.3%). Abnormal chest X-ray was observed in 14.3%. No patients reached the primary endpoint. Time to clinical recovery was shorter among patients who received HCQ, but this difference did not reach statistical significance. Conclusion Most of the patients with COVID-19 presented with mild disease and exhibited a clinical trajectory not similar to other countries. Outcomes did not differ by HCQ treatment status in line with other concluded studies on the benefit of using HCQ in the treatment of COVID-19.
Competing interests None declared. Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Patient consent for publication Not required. Ethics approval This study was conducted according to the principles of the Declaration of Helsinki and good clinical practice (GCP) as laid down by the ICH topic E6 (Note for Guidance on GCP). The study was approved by the Mulago Hospital Research and Ethics Committee (MHREC 1869). All patients provided written informed consent. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available at Makerere University Lung Institute upon reasonable request. Please contact Dr Bruce Kirenga for data requests. Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/. ORCID iD Bruce Kirenga http:// orcid. org/ 0000-0002-2023-2840
Arons, Hatfield, Reddy, Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility, N Engl J Med, doi:10.1056/NEJMoa2008457
Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Chen, Huang, Cheng, Favipiravir versus arbidol for COVID-19: a randomized clinical trial, medRxiv
Chu, Cheng, Hung, Viral load distribution in SARS outbreak, Emerg Infect Dis, doi:10.3201/eid1112.040949
Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2004168117
Garg, Kim, Whitaker, Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 States, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6915e3
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Grein, Ohmagari, Shin, Compassionate use of Remdesivir for patients with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2007016
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Heneghan, Brassey, SARS-CoV-2 viral load and the severity of COVID-19
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Kayima, Nankabirwa, Sinabulya, Determinants of hypertension in a young adult Ugandan population in copyright, BMC Public Health, doi:10.1186/s12889-015-2146-y
Kwarisiima, Balzer, Heller, Population-based assessment of hypertension epidemiology and risk factors among HIV-positive and general populations in rural Uganda, PLoS One, doi:10.1371/journal.pone.0156309
Liang, Guan, Li, Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China, Eur Respir J, doi:10.1183/13993003.00562-2020
Lunyera, Kirenga, Stanifer, Geographic differences in the prevalence of hypertension in Uganda: results of a national epidemiological study, PLoS One, doi:10.1371/journal.pone.0201001
Mehra, Desai, Kuy, Cardiovascular disease, drug therapy, and mortality in Covid-19, N Engl J Med, doi:10.1056/NEJMoa2007621
Morris, Cleary, Clarke, Secondary bacterial infections associated with influenza pandemics, Front Microbiol, doi:10.3389/fmicb.2017.01041
Phua, Weng, Ling, Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations, Lancet Respir Med, doi:10.1016/S2213-2600(20)30161-2
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA, doi:10.1001/jama.2020.6775
Sutton, Fuchs, 'alton, Universal screening for SARS-CoV-2 in women admitted for delivery, N Engl J Med, doi:10.1056/NEJMc2009316
Wei, Li, Chiew, Presymptomatic Transmission of SARS-CoV-2 -Singapore, January 23, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6914e1
Xu, Han, Li, Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2005615117
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop